Posts by Roy Perlis, MD, MSc
-
Persistent Cognitive Symptoms After COVID-19 Linked to Depression, Impaired Daily Function
Roy Perlis, MD, MSc, and colleagues found in a nationwide study that daily cognitive symptoms in people with post–COVID-19 condition are associated with greater functional impairment, reduced likelihood of full-time employment, and more severe depressive symptoms than in people who fully recovered from COVID-19.
-
Artificial Intelligence Promising As a Decision Support Tool When Treating Bipolar Depression
Roy H. Perlis, MD, MSc, and colleagues have demonstrated the potential utility of prompting GPT-4 with treatment guidelines for bipolar depression. The artificial intelligence model showed modest agreement with experts—and better performance than community physicians—in selecting the optimal next-step medication.
-
JAMA Network Open Publishes Criteria for Manuscripts Reporting Clinical Use of AI
Aiming to publish research on large language models (LLMs) as rapidly as the technology is evolving—while insisting on customary standards such as validity, fairness, and transparency—the editors of JAMA Network Open have developed criteria to guide authors submitting LLM-related reports.
-
Quality of Peer Reviews for a General Medical Journal Did Not Diminish During COVID-19 Pandemic
Roy H. Perlis, MD, MSc, and colleagues found the peer review process at JAMA Network Open continued to function well during the COVID-19 pandemic, with reviewer acceptance rates remaining steady and turnaround time and quality of reviews modestly improving, especially for COVID-19–focused manuscripts.
-
Neuropsychiatric Symptoms After COVID-19 Hospitalization No More Frequent Than After Other Hospitalizations
Victor M. Castro, MS, Roy Perlis, MD, MSc, and colleagues determined that new-onset neuropsychiatric symptoms are common up to 150 days after COVID-19 hospitalization. Still, rates are no higher than those hospitalized for other indications during the same period—and rates of some symptoms are substantially lower.
-
COVID-19 During Pregnancy: Q&A With Roy Perlis, MD, MSc
A preliminary study at Massachusetts General Hospital, co-led by Roy Perlis, MD, MSc, director of the Center for Quantitative Health, and Andrea Edlow, MD, MSc, an investigator in the Vincent Center for Reproductive Biology suggests that COVID-19 infection during pregnancy may lead to developmental delays in the child's early life. Dr. Perlis explains the study and its implications.
-
Depression Linked to Belief in Misinformation About COVID-19 Vaccines
Roy Perlis, MD, MSc, and colleagues found in a nationally representative U.S. survey that adults with at least moderate depressive symptoms are more likely than others to endorse misinformation about COVID-19 vaccines. A longitudinal subanalysis hints that depression treatment might help improve vaccination rates.
-
COVID-19 May Cause a Distinct Type of Major Depression
Roy H. Perlis, MD, MSc, of the Department of Psychiatry, and colleagues compared features of major depressive disorder in individuals with or without prior COVID-19. They found indirect evidence that symptoms are a sequela of COVID-19 pathophysiology in a subset of individuals.
-
Prenatal Diagnosis Codes Predict Maternal Morbidity, Aid in Risk Stratification
Mark A. Clapp, MD, MPH, Roy H. Perlis, MD, and colleagues demonstrated the potential utility of prenatal ICD-10 codes to identify a group of women who were more than 2 to 3.5 times more likely than others to have severe maternal morbidity.
-
Novel Cell Models Allow Study of How COVID-19, Other Maternal Exposures Affect the Fetal Brain
By reprogramming neonatal cord blood mononuclear cells, researchers at Massachusetts General Hospital have created patient-specific models of fetal microglia-mediated synaptic pruning. These will permit non-invasive investigation of how maternal exposures, including SARS-CoV-2 infection, affect the fetal brain.
-
Most Adults with ADHD Don't Renew Stimulant Prescriptions on a Timely Basis
Roy H. Perlis, MD, MSc, and Joseph Biederman, MD, of the Department of Psychiatry, provide real-world evidence of low rates of renewal of initial stimulant prescriptions by adults with attention-deficit/hyperactivity disorder, especially in primary care settings.
-
Psychiatric Evaluations Declined As COVID-19 Emerged in Boston
The need for quarantine and the strain on clinical resources may be reducing health systems' ability to respond to psychiatric symptoms.
-
Improvement Needed in Genetic Test–Guided Treatment of Major Depressive Disorder
The selection of antidepressants guided by a commercially available pharmacogenomic test did not result in differences in depression severity over eight weeks compared with treatment as usual.
-
How COVID-19 Could Affect Health Care Workers
Online survey results have shown that health care workers exposed to COVID-19 in China reported high rates of psychological distress.
-
Using EHR Data to Screen for Dementia May Facilitate Earlier Diagnosis
Researchers at Massachusetts General Hospital are the first to demonstrate that it's possible to identify individuals at risk of dementia years ahead of a formal diagnosis using natural language processing of electronic health records.
-
Using Machine Learning to Identify Suicide Risk
Applying natural language processing to hospital discharge notes made it possible to identify psychopathology associated with the timing of suicide risk and accidental death in a general hospital population.
-
Synaptic Pruning May Play a Role in the Development and Treatment of Schizophrenia
New research suggests a link between excessive synaptic pruning in human cells and schizophrenia—a major step towards disease prevention.
-
Psychosis in Young Adults with ADHD More Likely with Amphetamines Than Methylphenidate
According to a large study of claims data, new-onset psychosis affects about one in 660 adolescents and young adults with ADHD who begin taking stimulants, but the risk is doubled in those who start amphetamine compared with those who start methylphenidate.
-
First GWAS of Fracture Nonunion Identifies Novel Locus
In the first genome-wide association study of fracture nonunion, researchers at Massachusetts General Hospital have identified multiple loci that warrant investigation in the effort to address this costly outcome.
-
Use of Electronic Health Records Genetically Validated for Research Into Bipolar Disorder
Researchers at Mass General were involved in the first study to provide genetic validation of the use of electronic health records in bipolar disorder phenotyping, which should prove to be a boon to genetic research in psychiatry generally.
-
Novel Locus for Delirium Risk Identified
Researchers at Massachusetts General Hospital have performed the first genome-wide association study aimed at providing insight into the biological basis of delirium.
-
All Humans Carry Genetic Risk Factors for Major Depression
By conducting one of the largest genome-wide association studies in psychiatry, researchers have expanded the understanding of the genetics of major depression—and suggest a new approach to studying who is genetically at high-risk for poor outcomes.
Biography
Dr. Perlis is the associate chief for research in the Department of Psychiatry and director of the Center for Quantitative Health in the Division of Clinical Research at Massachusetts General Hospital, the Associate Director of the Psychiatric Genetics Program in Mood and Anxiety Disorders and Professor of Psychiatry at Harvard Medical School. He also serves as consultant to the American Psychiatric Association's bipolar treatment guidelines workgroup.
A graduate of Brown University, Harvard Medical School and Harvard School of Public Health, he completed his residency, chief residency, and clinical/research fellowship at Mass General before joining the faculty.
Dr. Perlis' clinical work and research is focused on difficult-to-treat or treatment resistant mood disorders, including major depressive disorder and bipolar disorder. He has authored more than 125 articles reporting original research, as well as numerous book chapters and reviews.
Current research efforts include identifying genetic variations which might predict treatment response, creating neuronal models of disease, and identifying and studying novel treatments for mood disorders.
His research has been supported by awards from NARSAD, NIMH, NSF, the American Philosophical Society, the Bowman Family Foundation, and the Stanley Center for Psychiatric Research, among others. In 2010 Dr. Perlis was awarded the Depression and Bipolar Support Alliance's Klerman Young Investigator Award.
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.